Background Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH)
clinically includes autoimmunity as indicated by antinuclear antibody (ANA) positivity and …

Aim To investigate the prevalence of biopsy-proven non-alcoholic steatohepatitis (NASH) in
a cohort of patients with morbid obesity and with or without type 2 diabetes (T2D) and to find …

Background, The pathogenesis of non-alcoholic steatohepatitis remains unclear from
several points of view. Minimal diagnostic criteria are still not defined. Aim. To gather …

Abstract Background & Aims Patients with non‐alcoholic steatohepatitis (NASH) have
increased mortality, including from infections. We, therefore, tested in a rodent model of …

Background Although several studies have been performed on risk factors and natural
course of NASH, it seems that NASH tends to be more than a disease confined to strict …

Results RMR did not significantly differ between patients with NASH and NAFLD without
steatohepatitis in both genders (p= 0.695 in males, p= 0.256 in females). However, only in …

: Non-alcoholic steatohepatitis (NASH), first described by Ludwig et al, in 1980, is a stage in
the wide spectrum of non-alcoholic fatty liver diseases (NAFLDs) and one of the leading …

Söderberg C, Marmur J, Eckes K, Glaumann H, Sällberg M, Frelin L, Rosenberg P, Stål P,
Hultcrantz R. Microvesicular fat, inter cellular adhesion molecule‐1 and regulatory T …

Non-alcoholic steatohepatitis (NASH) can vary from mild hepatic inflammation and steatosis
to cirrhosis, and is most frequently associated with obesity, Type 2 diabetes mellitus …

Abstract Purpose of Review To summarize experimental and clinical evidence on the
association between tumor necrosis factor-α (TNF-α) and nonalcoholic fatty liver disease …